MSD Animal Health Boosts Animal Vaccine Yield with XCell ATF® Intensification

Published on Repligen White Paper (July 2022)

Facing growing demand for veterinary vaccines, MSD Animal Health partnered with Repligen to test XCell ATF® perfusion technology for viral antigen production. Across small- and large-scale studies, the system achieved up to 5× higher cell density and viral output compared to batch culture, without added shear stress or filtration issues. Perfusion at the N‑1 stage also yielded ~3× more antigenic mass. These improvements simplify processing, reduce CAPEX, and enable scalable, closed-system vaccine manufacturing for global veterinary use.

Read the full white paper from Repligen:

👉 Investigation of XCell ATF® Perfusion Technology for Virus Manufacturing (PDF)

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.